Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrixetinib in relapsed or refractory chronic graft-versus-host disease
NCT07138196Phase 1Recruiting
- Sponsor
- Qurient Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adrixetinib in chronic graft-versus-host disease (cGVHD), sponsored by Qurient Co., Ltd. Primary endpoints: Number of Participants with Dose-Limiting Toxicities at 28 days and Number of Participants with Adverse Events and Serious Adverse Events at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
adrixetinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07138196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07138196.